NCT07633639Recruiting
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 18 May 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 May 2028
- Lead sponsor
- China-Japan Friendship Hospital
- Diseases
- Obesity
- NCT number
- NCT07633639
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 May 2026 to the primary completion date, 1 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
- Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
- Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
Other illness
- Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
Lab values
- Significant comorbidities:
- 5.1Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR \<30 mL/min/1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).
Who the study is looking for
- Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
- obesity:BMI ≥30 kg/m².
- Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
- Age range: 18-60 years (inclusive).
- Informed consent: Willing participation with documented consent.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China-Japan Friendship Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.